As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include an interesting publication on pediatric CML.

Read Professor Hughes' CML publications of the month: October 2024

Clinical CML papers

• Nilotinib versus dasatinib in achieving MR4.5 for de novo CML:
  The randomized JALSG CML212 study
  Matsumura I et al. Blood Adv, Oct 2024 – open access publication
• Tyrosine kinase inhibitor for CML: All the same?
  Veltmaat L & Cortes J. Blood Adv, Oct 2024 – open access publication
• Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic-phase:
  The ASC2ESCALATE Phase II trial
  Atallah E et al. Future Oncol, Oct 2024 (epub ahead of print) – open access publication
• Viral infections and incidence of reactivations in chronic myeloid leukemia patients
  Addapt MD et al. Oncology, Oct 2024 (epub ahead of print)
• Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: A systematic review and meta-analysis
  Zheng Z et al. Discov Oncol, Oct 2024 – open access publication
• Asciminib in advanced-line of treatment of CML
  Shacham-Abdulafia A et al. Eur J Haematol, Oct 2024 (epub ahead of print) – open access publication
• Intensification of upfront chemotherapy for patients with myeloid blast crisis in CML: A single centre experience
  Lee BJ et al. Ann Hematol, Oct 2024 (epub ahead of print) – open access publication
• Sudden blast crisis in a CML patient in treatment-free remission: A case report and literature review
  Liang Q et al. Acta Haematol, Oct 2024 (epub ahead of print)

Scientific CML papers

• The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies
  Yu M et al. Leukemia, Oct 2024 (epub ahead of print)
• Computationally driven discovery of a BCR::ABL1 kinase inhibitor with activity in multi-drug resistant CML
  Hill J et al. J Med Chem, Oct 2024 – open access publication

Pediatric papers

• Clinical characteristics and outcomes of CML in adolescents and young adults
  Al Rabi K et al. Clin Lymphoma Myeloma Leuk, Oct 2024
  
  

Read Professor Hughes' summaries of key CML publications

This series of paper summaries is an extension of Professor Tim Hughes' 'CML publications of the month' news service.
These summaries, selected and curated by Professor Hughes, will be compiled and provided every three months, offering a comprehensive overview of key CML papers. This approach ensures that clinicians, researchers, and healthcare professionals stay up-to-date with important pivotal studies and emerging trends in CML research.

CML paper summary #2  - October 2024: Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in CML patients (Sala-Torra O et al. Leukemia, June 2024)
Link to full paper (Leukemia (2024) 38:1822–1824)

This study published in Leukemia explores a novel method for monitoring BCR::ABL1 transcripts in CML patients using a point-of-care dried capillary blood (DCB) collection system. The primary goal was to assess the correlation between BCR::ABL1 transcript levels in DCB and standard venous blood samples.

View the paper summary here

Read more